Tocqueville Asset Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Tocqueville Asset Management’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-70,000	Closed	-$508K	–	840
2016 Q3	$508K	Hold	70,000	–	–	0.01%	629
2016 Q2	$584K	Hold	70,000	–	–	0.01%	606
2016 Q1	$466K	Hold	70,000	–	–	0.01%	654
2015 Q4	$599K	Buy	70,000 +10,000	+17%	+$75.8K	0.01%	627
2015 Q3	$328K	Buy	60,000 +20,000	+50%	+$126K	﹤0.01%	789
2015 Q2	$227K	Hold	40,000	–	–	﹤0.01%	900
2015 Q1	$255K	Hold	40,000	–	–	﹤0.01%	850
2014 Q4	$182K	Buy	40,000 +15,000	+60%	+$98.6K	﹤0.01%	911
2014 Q3	$203K	Buy	25,000 +10,000	+67%	+$88.9K	﹤0.01%	812
2014 Q2	$144K	Hold	15,000	–	–	﹤0.01%	1056
2014 Q1	$177K	Buy	+15,000	New	+$253K	﹤0.01%	820

Other funds holding ORMP

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

AIM

Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

FNBT

FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return

SIAP

Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Tocqueville Asset Management's ORMP Position: Q4 2016 in Review

Tocqueville Asset Management sold out of Oramed Pharmaceuticals (ORMP) in Q4 2016, closing a stake of 70,000 shares — an estimated $508K sold.

Tocqueville Asset Management first reported a position in ORMP in Q1 2014 and held it in 11 quarters. The position peaked at $599K in Q4 2015. 24 funds tracked by Wall St. Rank hold ORMP as of Q4 2016.

Tocqueville Asset Management reported no remaining Oramed Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Tocqueville Asset Management sold 70,000 Oramed Pharmaceuticals shares in Q4 2016, an estimated $508K.
Tocqueville Asset Management first reported a position in Oramed Pharmaceuticals in Q1 2014 and held it in 11 quarters.
Tocqueville Asset Management's Oramed Pharmaceuticals position peaked at $599K in Q4 2015.
24 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2016.

Based on Tocqueville Asset Management's 13F filing for Q4 2016, filed 30 Jan 2017.